At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 29 enrolled
Drug / intervention
AZD9291 +1 moredrug
Likely dose
AZD9291 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination With MEDI4736 Versus AZD9291 Monotherapy in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)
In Brief
A Phase 3 clinical trial evaluating AZD9291 and MEDI4736 for Locally Advanced or Metastatic EGFR T790M+ NSCLC. Completed, enrolled 29 participants across 13 sites in 3 countries.
Detailed Summary
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionAug 2017
Study CompletionJun 2023
TodayJul 2026
First PostedMay 27, 2015
Enrollment StartJul 15, 2015
Primary CompletionAug 21, 2017
Study CompletionJun 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.1 years ago
Interventions
AZD9291drug
Once daily tablet 80 mg
MEDI4736drug
10mg/kg q2w (IV) infusion